XEN053

About Xenon Pharmaceuticals

Xenon Pharmaceuticals is a Canadian biotech pioneer utilizing human genetics to identify and validate novel drug targets, primarily within the ion channel space, for the treatment of neurological and other disorders. Its most advanced asset, XEN1101, a Kv7 potassium channel opener, has demonstrated positive Phase 2b results in major depressive disorder (MDD) and focal onset seizures, positioning it for pivotal Phase 3 trials. The company's strategy combines internal development of its core pipeline with strategic collaborations, such as its ongoing partnership with Neurocrine Biosciences, to advance its genetic discovery platform and expand its therapeutic reach.

Therapeutic Areas